Industry / United Kingdom

Eisai Open European Knowledge Centre

June 2009 | Industry Trend Analysis

Printable version
Bookmark

Despite the local pricing regulator recently turning down the expanded use of its key drug, Japanese pharmaceutical company

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Fujifilm Buys Merck & Co's Biomanufacturing Network

Industry / United Kingdom BMI Core View: Non-healthcare companies, particularly technology firms, will increasingly enter the medical services sector. Companies see healthcare as a sustainable and expanding business, principally...

March 2011

GSK Reveals Recovery Strategy

Industry / United Kingdom BMI View: India's pharmaceutical market beguiles multinational pharmaceutical companies. Sales of medicines are booming and red tape will prevent systematic price cuts, which is a nascent trend in developing...

February 2011

Differential Pricing: A Key Strategy To Boost Sales In Emerging Markets

Industry / United Kingdom BMI Core View: Drugmakers will increasingly use differential pricing in emerging markets. Pharmaceutical companies generally price their patented medicines at the maximum the market will bear in light...

January 2011

Leading Drugmaker Highlights Concerning Situation

Industry / United Kingdom GlaxoSmithKline Pakistan's financial performance has been impaired by a challenging business environment, according to the company's senior executive. In an interview with Bloomberg, Chairman and CEO M....

July 2010

GSK To Increase Its Investment In Asia

Industry / United Kingdom Multinational drugmaker GlaxoSmithKline (GSK) is looking to invest in small- and medium-sized pharmaceutical and biotechnology companies in Japan, reinforcing the company's strategic priority - to grow...

March 2010